Since launching the 18 Series in the U.S., Cosmos Health has introduced five products: Noor18™, Liv18™, Cur18™, Fort18™, and Oliv18™ — four of which currently have disclosed projections. The Company has observed encouraging early demand and continues to build commercial traction in the U.S. market.
Across the four products with disclosed projections to date, Cosmos Health is targeting over $22.7 million in annualized U.S. revenue and approximately $17.0 million in implied gross profit at ~75% gross margins.
18 Series — Announced U.S. Revenue and Gross Profit Projections
| Product | Category | Projected Annualized U.S. Revenue | Gross Profit¹ |
| Noor18™ | Healthy aging / beauty | Over $12.0M | ~$9.00M |
| Liv18™ | Liver & metabolic support | Over $5.0M | ~$3.75M |
| Fort18™ | Men's wellness | Over $3.2M | ~$2.40M |
| Cur18™ | Inflammation & mobility | Over $2.5M | ~$1.875M |
| Total | Over $22.7M | ~$17.0M |
¹ Gross profit is calculated by applying the Company's approximately 75% gross-margin guidance to its disclosed revenue projections. Total excludes Oliv18™, which is launched but has no disclosed revenue projection.
The 18 Series platform remains at an early stage. Cosmos Health is targeting a portfolio of 18 science-based products spanning key health categories, and expects to provide further updates as additional products are launched and commercial data develops.
The Company expects its U.S. 18 Series to become a significant pillar of long-term revenue and a meaningful contributor to profitability.
Login to comment